Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sembragiline

Drug Profile

Sembragiline

Alternative Names: EVT-302; RG-1577; RO-4602522

Latest Information Update: 25 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Evotec SE; Roche
  • Class Acetanilides; Nootropics; Pyrrolidines; Small molecules; Smoking cessation therapies
  • Mechanism of Action Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Discontinued Smoking withdrawal

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 08 Sep 2016 Phase II development is ongoing in Australia, Canada, Czech Republic, France, Germany, Italy, Poland, South Korea, Spain, Sweden, United Kingdom and USA (Evotec pipeline, September 2016)
  • 30 Jun 2015 Interim efficacy and safety data from a phase-II trial in Alzheimer's disease released by Roche (NCT01677754)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top